The Global Central Lab Market overview: Central lab testing plays a crucial role in providing analytical testing services to clinical trials and pharmaceutical companies helping accelerate drug development. Central labs offer a wide range of testing ranging from clinical chemistry, hematology, urinalysis, immunology, endocrinology and more. They provide robust project management, quality processes and global reach to support clinical trials at any stage and geographical location.
The Global Central Lab Market is estimated to be valued at US$ 3.40 Billion in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period from 2024 to 2031.
Key Takeaways
Key players: Key players operating in the Global Central Lab Market are ACM Global Laboratories, Barc Lab (Cerba Research), Bioscientia (Sonic Healthcare), Celerion, CIRION BioPharma Research, Clinical Reference Laboratory, Eurofins Central Laboratory, Frontage Laboratories, Inc., ICON Central Laboratories, INTERLAB Central Lab Services, InVitro International, Labcorp/Covance, LabConnect, Medpace, MLM Medical Labs GmbH, PPD and Q² Solutions.
Growing demand: There Global Central Lab Market Demand trial activity and outsourcing of lab testing requirements by biopharma companies. Central labs help streamline operations, ensure quality standards and scale up testing capacity according to project needs.
Global expansion: Key players are expanding their geographic footprint to tap growing opportunities in emerging markets. Many central labs have a network of labs worldwide to provide custom projects support across regions and countries. This allows for efficient project management and faster turnaround times.
Market Key Trends
Global central lab market Size And Trends Many players are deploying LIMS, laboratory automation, AI/machine learning applications to improve workflow efficiency, data analytics capabilities and drive standardization. This allows for higher sample throughput, reduced turnaround times and improved data quality. In addition, growing focus on specialty testing services especially in the areas of biomarkers, companion and complementary diagnostics is expected to drive future growth in the central lab market over the forecast period from 2024 to 2031.
Porter’s Analysis
Threat of new entrants: Low startup costs and government certification barriers make threat of new entrants low in this market.
Bargaining power of buyers: Large diagnostic networks and hospital chains have strong bargaining power over centralized labs as they can choose from a variety of lab providers.
Bargaining power of suppliers: Due to demand for advanced diagnostic equipment and technologies, centralized labs have weak bargaining power over suppliers like diagnostic device manufacturers.
Threat of new substitutes: With lack of direct substitutes, threat of new substitutes is low for centralized labs currently.
Competitive rivalry: High as major lab chains compete to gain market share through improved services, quality, lower turnaround times and expansion into new geographies.
Geographical Regions
North America accounts for the largest share of the global central lab market currently, valued at around US$ 1.30 Bn in 2024 owing to well-established healthcare infrastructure and increasing dependence on diagnostic tests in the region.
The Asia Pacific region is expected to be the fastest growing market during the forecast period driven by growing healthcare expenditure, increasing incidences of chronic diseases and focus of key players on expanding presence in emerging countries in the region.
Get More Insights On, Global Central Lab Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
0 comment